Elcrit

Elcrit uses

• Indications and usage
• Dosage and administration
• Dosage forms and strengths
• Contraindications
• Warnings and precautions
• Adverse reactions
• Drug interactions
• Use in specific populations
• Overdosage
• Description
• Clinical pharmacology
• Nonclinical toxicology
• Clinical studies
• How supplied/storage and handling
• Patient counseling information
• Patient information
• Elcrit reviews

1 INDICATIONS AND USAGE

Elcrit is an atypical antipsychotic indicated for:

• Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study.
• Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study (1.2, 14.2).

1.1 Treatment-Resistant Schizophrenia

Elcrit is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Elcrit should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see Warnings and Precautions (5.1, 5.5) ].

The effectiveness of Elcrit in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing Elcrit and chlorpromazine in patients who had failed other antipsychotics .

1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorders

Elcrit is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.

The effectiveness of Elcrit in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePT trial .

2 DOSAGE AND ADMINISTRATION

• Starting Dose: 12.5 mg once daily or twice daily.
• Use cautious titration and divided dosage schedule (2.2, 5.3).
• Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated (2.2).
• Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks (2.2).
• Subsequent increases: increase in increments of 100 mg or less, once or twice weekly (2.2).
• Maximum daily dose: 900 mg (2.2).
• Administer orally using syringe provided (2.3).
• Shake bottle for 10 seconds prior to withdrawing suspension from bottle; use oral syringes and syringe adaptor provided (2.3).

2.1 Required Laboratory Testing Prior to Initiation and During Therapy

Prior to initiating treatment with Elcrit, a baseline ANC must be obtained. The baseline ANC must be at least 1500/µL for the general population, and at least 1000/µL for patients with documented Benign Ethnic Neutropenia (BEN). To continue treatment, the ANC must be monitored regularly .

2.2 Dosing Information

The starting dose is 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to achieve a target dose of 300 mg to 450 mg per day by the end of 2 weeks. Subsequently, the dose can be increased once weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. To minimize the risk of orthostatic hypotension, bradycardia, and syncope, it is necessary to use this low starting dose, gradual titration schedule, and divided dosages [see Warnings and Precautions (5.3) ].

2.3 Important Administration Instructions

Elcrit Oral Suspension is administered to the mouth by the oral syringes provided (1 mL or 9 mL). After shaking the bottle for 10 seconds prior to each use, the syringe adaptor is pressed on top of the bottle. The oral syringe (1 mL or 9 mL) is filled with air, and inserted into the adaptor. The air is dispelled into the bottle and then the bottle is turned upside down. The prescribed amount of the suspension is drawn from the bottle and dispensed directly to the mouth. The prescribed dose should be administered immediately after it is prepared. Do not draw a dose and store it in the syringe for later use. After use, the oral syringe may be washed with warm water and dried for next use. The bottle may be closed with the same cap without removing the bottle adaptor. Educate patients and caregivers on the steps to administer Elcrit as described in the Patient Instructions for Use.

Elcrit can be taken with or without food .

2.4 Maintenance Treatment

Generally, patients responding to Elcrit should continue maintenance treatment on their effective dose beyond the acute episode.

2.5 Discontinuation of Treatment

Method of treatment discontinuation will vary depending on the patient's last ANC:

• See Tables 2 or 3 for appropriate ANC monitoring based on the level of neutropenia if abrupt treatment discontinuation is necessary because of moderate to severe neutropenia.
• Reduce the dose gradually over a period of 1 to 2 weeks if termination of Elcrit therapy is planned and there is no evidence of moderate to severe neutropenia.
• For abrupt Elcrit discontinuation for a reason unrelated to neutropenia, continuation of the existing ANC monitoring is recommended for general population patients until their ANC is ≥1500/µL and for BEN patients until their ANC is ≥1000/µL or above their baseline.
• Additional ANC monitoring is required for any patient reporting onset of fever during the 2 weeks after discontinuation [see Warnings and Precautions (5.1) ].
• Monitor all patients carefully for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as profuse sweating, headache, nausea, vomiting, and diarrhea.

2.6 Re-Initiation of Treatment

When restarting Elcrit in patients who have discontinued Elcrit (i.e., 2 days or more since the last dose), re-initiate with 12.5 mg once daily or twice daily. This is necessary to minimize the risk of hypotension, bradycardia, and syncope . If that dose is well tolerated, the dose may be increased to the previously therapeutic dose more quickly than recommended for initial treatment.

2.7 Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers

Dose adjustments may be necessary in patients with concomitant use of: strong CYP1A2 inhibitors ; moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline); CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John’s wort, and rifampin); or CYP1A2 inducers (e.g., tobacco smoking) (Table 1) .

Table 1: Dose Adjustment in Patients Taking Concomitant Medications

2.8 Renal or Hepatic Impairment, or CYP2D6 Poor Metabolizers

It may be necessary to reduce the Elcrit dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers [see Use in Specific Populations (8.6, 8.7) ].

3 DOSAGE FORMS AND STRENGTHS

Elcrit is available as a free-flowing yellow oral suspension. Each mL contains 50 mg of Elcrit.

• Oral suspension: 50 mg per mL (3).

4 CONTRAINDICATIONS

• Known hypersensitivity to Elcrit or any other component of Elcrit.

4.1 Hypersensitivity

Elcrit is contraindicated in patients with a history of serious hypersensitivity to Elcrit (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of Elcrit .

5 WARNINGS AND PRECAUTIONS

• Eosinophilia: Assess for organ involvement. Discontinue if these occur (5.8).
• QT Interval Prolongation: Can be fatal. Consider additional risk factors for prolonged QT interval (disorders and drugs) (5.9).
• Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include:
  • Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes (5.10).
  • Dyslipidemia: Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics (5.10).
  • Weight Gain: Significant weight gain has occurred. Monitor weight gain (5.10).
• Neuroleptic Malignant Syndrome (NMS): Immediately discontinue and monitor closely. Assess for co-morbid conditions (5.11).
• Hepatotoxicity: Can be fatal. Monitor for hepatotoxicity. Discontinue treatment if hepatitis or transaminase elevations combined with other symptoms occur (5.12).
• Fever: Evaluate for infection, and for neutropenia, NMS (5.13).
• Pulmonary Embolism (PE): Consider PE if respiratory distress, chest, pain, or deep vein thrombosis occurs (5.14).
• Anticholinergic Toxicity: Use cautiously in presence of specific conditions (e.g., narrow angle glaucoma, use of anticholinergic drugs) (5.15).
• Interference with Cognitive and Motor Performance: Advise caution when operating machinery, including automobiles (5.16).

5.1 Severe Neutropenia

Background

Elcrit can cause neutropenia (a low absolute neutrophil count [ANC]), defined as a reduction below pre-treatment normal levels of blood neutrophils. The ANC is usually available as a component of the complete blood count (CBC), including differential, and is more relevant to drug-induced neutropenia than is the white blood cell (WBC) count. The ANC may also be calculated using the following formula: ANC equals the Total WBC count multiplied by the total percentage of neutrophils obtained from the differential (neutrophil “segs” plus neutrophil “bands”). Other granulocytes (basophils and eosinophils) contribute minimally to neutropenia and their measurement is not necessary [see Adverse Reactions (6.2) ]. Neutropenia may be mild, moderate, or severe. To improve and standardize understanding, “severe neutropenia” replaces the previous terms severe leukopenia, severe granulocytopenia, or agranulocytosis.

Severe neutropenia, ANC less than (<) 500/µL, occurs in a small percentage of patients taking Elcrit and is associated with an increase in the risk of serious and potentially fatal infections. Risk of neutropenia appears greatest during the first 18 weeks on treatment and then declines. The mechanism by which Elcrit causes neutropenia is unknown and is not dose-dependent.

Two separate management algorithms are provided below, the first for patients in the general population, and the second for patients identified to have baseline neutropenia.

Elcrit Treatment and Monitoring in the General Patient Population

Obtain a CBC, including the ANC value, prior to initiating treatment with Elcrit to ensure the presence of a normal baseline neutrophil count (equal to or greater than 1500/µL) and to permit later comparisons. Patients in the general population with an ANC equal to or greater than (≥) 1500/µL are considered within normal range (Table 2) and are eligible to initiate treatment. Weekly ANC monitoring is required for all patients during the first 6 months of treatment. If a patient's ANC remains equal to or greater than 1500/µL for the first 6 months of treatment, monitoring frequency may be reduced to every 2 weeks for the next 6 months. If the ANC remains equal to or greater than 1500/µL for the second 6 months of continuous therapy, ANC monitoring frequency may be reduced to once every 4 weeks thereafter.

Table 2: Elcrit Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring for the General Patient Population

* Confirm all initial reports of ANC less than 1500/µL with a repeat ANC measurement within 24 hours

** If clinically appropriate

Elcrit Treatment and Monitoring in Patients with Benign Ethnic Neutropenia

Benign ethnic neutropenia (BEN) is a condition observed in certain ethnic groups whose average ANC values are lower than “standard” laboratory ranges for neutrophils. It is most commonly observed in individuals of African descent (approximate prevalence of 25-50%), some Middle Eastern ethnic groups, and in other non-Caucasian ethnic groups with darker skin. BEN is more common in men. Patients with BEN have normal hematopoietic stem-cell number and myeloid maturation, are healthy, and do not suffer from repeated or severe infections. They are not at increased risk for developing VERSACLOZ-induced neutropenia. Additional evaluation may be needed to determine if baseline neutropenia is due to BEN. Consider hematology consultation before initiating or during Elcrit treatment as necessary.

Patients with BEN require a different ANC algorithm for Elcrit management due to their lower baseline ANC levels. Table 3 provides guidelines for managing Elcrit treatment and ANC monitoring in patients with BEN.

Table 3: Patients with Benign Ethnic Neutropenia (BEN); Elcrit Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring

* Confirm all initial reports of ANC less than 1500/µL with a repeat ANC measurement within 24 hours

** If clinically appropriate

General Guidelines for Management of All Patients with Fever or with Neutropenia

• Fever: Interrupt Elcrit as a precautionary measure in any patient who develops fever, defined as a temperature of 38.5°C [101.3°F] or greater, and obtain an ANC level. Fever is often the first sign of neutropenic infection.
• ANC less than 1000/µL: If fever occurs in any patient with an ANC less than 1000/µL, initiate appropriate workup and treatment for infection and refer to Tables 2 or 3 for management.
• Consider hematology consultation.
• See Neuroleptic Malignant Syndrome (NMS) and Fever under WARNINGS AND PRECAUTIONS (5) and Instructions for Patients, under PATIENT COUNSELING INFORMATION (17).

Rechallenge after an ANC less than 500/µL (severe neutropenia)

For some patients who experience severe VERSACLOZ-related neutropenia, the risk of serious psychiatric illness from discontinuing Elcrit treatment may be greater than the risk of rechallenge (e.g., patients with severe schizophrenic illness who have no treatment options other than Elcrit). A hematology consultation may be useful in deciding to rechallenge a patient. In general, however, do not rechallenge patients who develop severe neutropenia with Elcrit or a Elcrit product.

If a patient will be rechallenged, the clinician should consider thresholds provided in Tables 2 and 3, the patient's medical and psychiatric history, a discussion with the patient and his/her caregiver about the benefits and risks of Elcrit rechallenge, and the severity and characteristics of the neutropenic episode.

Using Elcrit with Other Drugs Associated with Neutropenia

It is unclear if concurrent use of other drugs known to cause neutropenia increases the risk or severity of VERSACLOZ-induced neutropenia. There is no strong scientific rationale to avoid Elcrit treatment in patients concurrently treated with these drugs. If Elcrit is used concurrently with an agent known to cause neutropenia (e.g., some chemotherapeutic agents), consider monitoring patients more closely than the treatment guidelines provided in Tables 2 and 3. Consult with the treating oncologist in patients receiving concomitant chemotherapy.

5.2 Elcrit REMS Program

Elcrit is only available through a restricted program under a REMS called the Elcrit REMS Program because of the risk of severe neutropenia.

Notable requirements of the Elcrit REMS Program include:

• Healthcare professionals who prescribe Elcrit must be certified with the program by enrolling and completing training.
• Patients who receive Elcrit must be enrolled in the program and comply with the ANC testing and monitoring requirements.
• Pharmacies dispensing Elcrit must be certified with the program by enrolling and completing training and must only dispense to patients who are eligible to receive Elcrit.

Further information is available at www.clozapinerems.com or 1-844-267-8678.

5.3 Orthostatic Hypotension, Bradycardia, and Syncope

Hypotension, bradycardia, syncope, and cardiac arrest have occurred with Elcrit treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally mediated reflex bradycardia.

Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions . Consider reducing the dose if hypotension occurs. When restarting patients who have had even a brief interval off Elcrit (i.e., 2 days or more since the last dose), re-initiate treatment at 12.5 mg once daily or twice daily .

Use Elcrit cautiously in patients with cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (e.g., concomitant use of antihypertensives, dehydration and hypovolemia).

5.4 Falls

Elcrit may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic treatment.

5.5 Seizures

Seizure has been estimated to occur in association with Elcrit use at a cumulative incidence at one year of approximately 5%, based on the occurrence of one or more seizures in 61 of 1743 patients exposed to Elcrit during its clinical testing prior to domestic marketing. The risk of seizure is dose-related. Initiate treatment with a low dose (12.5 mg), titrate slowly, and use divided dosing.

Use caution when administering Elcrit to patients with a history of seizures or other predisposing risk factors for seizure (e.g., head trauma or other CNS pathology, use of medications that lower the seizure threshold, or alcohol abuse). Because of the substantial risk of seizure associated with Elcrit use, caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others (e.g., driving an automobile, operating complex machinery, swimming, climbing).

5.6 Myocarditis and Cardiomyopathy

Myocarditis and cardiomyopathy have occurred with the use of Elcrit. These reactions can be fatal. Discontinue Elcrit and obtain a cardiac evaluation upon suspicion of myocarditis or cardiomyopathy. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with Elcrit. However, if the benefit of Elcrit treatment is judged to outweigh the potential risks of recurrent myocarditis or cardiomyopathy, the clinician may consider rechallenge with Elcrit in consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring.

Consider the possibility of myocarditis or cardiomyopathy in patients receiving Elcrit who present with chest pain, dyspnea, persistent tachycardia at rest, palpitations, fever, flu-like symptoms, hypotension, other signs or symptoms of heart failure, or electrocardiographic findings (low voltages, ST-T abnormalities, arrhythmias, right axis deviation, and poor R wave progression). Myocarditis most frequently presents within the first two months of Elcrit treatment. Symptoms of cardiomyopathy generally occur later than clozapine-associated myocarditis and usually after 8 weeks of treatment. However, myocarditis and cardiomyopathy can occur at any period during treatment with Elcrit. It is common for nonspecific flu-like symptoms such as malaise, myalgia, pleuritic chest pain, and low-grade fevers to precede more overt signs of heart failure. Typical laboratory findings include elevated troponin I or T, elevated creatinine kinase-MB, peripheral eosinophilia, and elevated C-reactive protein (CRP). Chest roentgenogram may demonstrate cardiac silhouette enlargement, and cardiac imaging (echocardiogram, radionucleotide studies, or cardiac catheterization) may reveal evidence of left ventricular dysfunction.

5.7 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality in this population. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Elcrit is not approved for the treatment of patients with dementia-related psychosis .

5.8 Eosinophilia

Eosinophilia, defined as a blood eosinophil count of greater than 700/μL, has occurred with Elcrit treatment. In clinical trials, approximately 1% of patients developed eosinophilia. Clozapine-related eosinophilia usually occurs during the first month of treatment. In some patients, it has been associated with myocarditis, pancreatitis, hepatitis, colitis, and nephritis. Such organ involvement could be consistent with a drug reaction with eosinophilia and systemic symptoms syndrome (DRESS), also known as drug induced hypersensitivity syndrome (DIHS). If eosinophilia develops during Elcrit treatment, evaluate promptly for signs and symptoms of systemic reactions, such as rash or other allergic symptoms, myocarditis, or other organ-specific disease associated with eosinophilia. If clozapine-related systemic disease is suspected, discontinue Elcrit immediately.

If a cause of eosinophilia unrelated to Elcrit is identified (e.g., asthma, allergies, collagen vascular disease, parasitic infections, and specific neoplasms), treat the underlying cause and continue Elcrit.

Clozapine-related eosinophilia has also occurred in the absence of organ involvement and can resolve without intervention. There are reports of successful rechallenge after discontinuation of Elcrit, without recurrence of eosinophilia. In the absence of organ involvement, continue Elcrit under careful monitoring. If the total eosinophil count continues to increase over several weeks in the absence of systemic disease, the decision to interrupt Elcrit therapy and rechallenge after the eosinophil count decreases should be based on the overall clinical assessment, in consultation with an internist or hematologist.

5.9 QT Interval Prolongation

QT prolongation, Torsades de Pointes and other life-threatening ventricular arrhythmias, cardiac arrest, and sudden death have occurred with Elcrit treatment. When prescribing Elcrit, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, long QT syndrome, family history of long QT syndrome or sudden cardiac death, significant cardiac arrhythmia, recent myocardial infarction, uncompensated heart failure, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of Elcrit, and electrolyte abnormalities.

Prior to initiating treatment with Elcrit, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue Elcrit if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with Torsades de Pointes or other arrhythmias,, obtain a cardiac evaluation and discontinue Elcrit.

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of Elcrit. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmic (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Elcrit is primarily metabolized by CYP isoenzymes 1A2, 2D6, and 3A4. Concomitant treatment with inhibitors of these enzymes can increase the concentration of Elcrit .

Hypokalemia and hypomagnesemia increase the risk of QT prolongation. Hypokalemia can result from diuretic therapy, diarrhea, and other causes. Use caution when treating patients at risk for significant electrolyte disturbance, particularly hypokalemia. Obtain baseline measurements of serum potassium and magnesium levels, and periodically monitor electrolytes. Correct electrolyte abnormalities before initiating treatment with Elcrit.

5.10 Metabolic Changes

Atypical antipsychotic drugs, including Elcrit, have been associated with metabolic changes that can increase cardiovascular and cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including Elcrit. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics are not available.

Patients with an established diagnosis of diabetes mellitus who are started on Elcrit should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

In a pooled data analysis of 8 studies in adult subjects with schizophrenia, the mean changes in fasting glucose concentration in the Elcrit and chlorpromazine groups were +11 mg/dL and +4 mg/dL respectively. A higher proportion of the Elcrit group demonstrated categorical increases from baseline in fasting glucose concentrations, compared to the chlorpromazine group (Table 4). The Elcrit doses were 100-900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for Elcrit and chlorpromazine.

Table 4: Categorical Changes in Fasting Glucose Level in Studies in Adult Subjects with Schizophrenia

Dyslipidemia

Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics, including Elcrit. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using Elcrit, is recommended.

In a pooled data analysis of 10 studies in adult subjects with schizophrenia, Elcrit treatment was associated with increases in serum total cholesterol. No data were collected on LDL and HDL cholesterol. The mean increase in total cholesterol was 13 mg/dL in the Elcrit group and 15 mg/dL in the chlorpromazine group. In a pooled data analysis of 2 studies in adult subjects with schizophrenia, Elcrit treatment was associated with increases in fasting serum triglyceride. The mean increase in fasting triglyceride was 71 mg/dL (54%) in the Elcrit group and 39 mg/dL (35%) in the chlorpromazine group (Table 5). In addition, Elcrit treatment was associated with categorical increases in serum total cholesterol and triglyceride, as illustrated in Table 6. The proportion of patients with categorical increases in total cholesterol or fasting triglyceride increased with the duration of exposure. The median duration of Elcrit and chlorpromazine exposure was 45 days and 38 days, respectively. The Elcrit dose range was 100 mg to 900 mg daily; the maximum chlorpromazine dose was 1800 mg daily.

Table 5: Mean Changes in Total Cholesterol and Triglyceride Concentration in Studies in Adult Subjects with Schizophrenia

Table 6: Categorical Changes in Lipid Concentrations in Studies in Adult Subjects with Schizophrenia

Weight Gain

Weight gain has occurred with the use of antipsychotics, including Elcrit. Monitor weight during treatment with Elcrit. Table 7 summarizes the data on weight gain by the duration of exposure pooled from 11 studies with Elcrit and active comparators. The median duration of exposure was 609, 728, and 42 days, in the Elcrit, olanzapine, and chlorpromazine group, respectively.

Table 7: Mean Change in Body Weight (kg) by duration of exposure from studies in adult subjects with schizophrenia

Table 8 summarizes pooled data from 11 studies in adult subjects with schizophrenia demonstrating weight gain ≥7% of body weight relative to baseline. The median duration of exposure was 609, 728, and 42 days, in the Elcrit, olanzapine, and chlorpromazine group, respectively.

Table 8: Proportion of adult subjects in schizophrenia studies with weight gain ≥7% relative to baseline body weight

5.11 Neuroleptic Malignant Syndrome

Antipsychotic drugs including Elcrit can cause a potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Associated findings can include elevated creatine phosphokinase (CPK), myoglobinuria, rhabdomyolysis, and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., severe neutropenia, infection, heat stroke, primary CNS pathology, central anticholinergic toxicity, extrapyramidal symptoms, and drug fever).

The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of co-morbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics.

NMS has occurred with Elcrit monotherapy and with concomitant CNS-active medications, including lithium.

5.12 Hepatotoxicity

Severe, life threatening, and in some cases fatal hepatotoxicity including hepatic failure, hepatic necrosis, and hepatitis have been reported in patients treated with Elcrit [see Adverse Reactions (6.2) ] . Monitor for the appearance of signs and symptoms of hepatotoxicity such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy. Perform serum tests for liver injury and consider permanently discontinuing treatment if hepatitis or transaminase elevations combined with other systemic symptoms are due to Elcrit.

5.13 Fever

During Elcrit therapy, patients have experienced transient, clozapine-related fever. The peak incidence is within the first 3 weeks of treatment. While this fever is generally benign and self-limited, it may necessitate discontinuing treatment. The fever can be associated with an increase or decrease in WBC count. Carefully evaluate patients with fever to rule out severe neutropenia or infection. Consider the possibility of NMS [see Warnings and Precautions ].

5.14 Pulmonary Embolism

Pulmonary embolism and deep vein thrombosis have occurred in patients treated with Elcrit. Consider the possibility of pulmonary embolism in patients who present with deep vein thrombosis, acute dyspnea, chest pain, or with other respiratory signs and symptoms. Whether pulmonary embolus and deep vein thrombosis can be attributed to Elcrit or some characteristic(s) of patients is not clear.

5.15 Anticholinergic Toxicity

Elcrit has potent anticholinergic effects. Treatment with Elcrit can result in CNS and peripheral anticholinergic toxicity. Use with caution in the presence of narrow-angle glaucoma, concomitant anticholinergic medications, prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions.

Treatment with Elcrit can result in gastrointestinal adverse reactions, including constipation, intestinal obstruction, fecal impaction, and paralytic ileus. Such reactions can be fatal. Constipation should be initially treated by ensuring adequate hydration and use of ancillary therapy such as bulk laxatives. Consultation with a gastroenterologist is advisable in more serious cases.

5.16 Interference with Cognitive and Motor Performance

Elcrit can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that Elcrit does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.

5.17 Tardive Dyskinesia

Tardive dyskinesia has occurred in patients treated with antipsychotic drugs, including Elcrit. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements. The risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses. However, the syndrome can develop after relatively brief treatment periods at low doses. Prescribe Elcrit in a manner that is most likely to minimize the risk of developing TD. Use the lowest effective dose and the shortest duration necessary to control symptoms. Periodically assess the need for continued treatment. Consider discontinuing treatment if TD occurs. However, some patients may require treatment with Elcrit despite the presence of the syndrome.

There is no known treatment for TD. However, the syndrome may remit partially or completely if treatment is discontinued. Antipsychotic treatment, itself, may suppress (or partially suppress) the signs and symptoms, and it has the potential to mask the underlying process. The effect of symptom suppression on the long-term course of TD is unknown.

5.18 Cerebrovascular Adverse Reactions

In controlled trials, elderly patients with dementia-related psychosis treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for Elcrit or other antipsychotics or other patient populations. Elcrit should be used with caution in patients with risk factors for cerebrovascular adverse reactions.

5.19 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of Elcrit

If abrupt discontinuation of Elcrit is necessary (because of severe neutropenia or another medical condition, for example) , monitor carefully for the recurrence of psychotic symptoms and adverse reactions related to cholinergic rebound, such as profuse sweating, headache, nausea, vomiting and diarrhea.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

• Severe Neutropenia .
• Orthostatic Hypotension, Bradycardia, and Syncope .
• Falls
• Seizures [see Warnings and Precautions (5.5) ].
• Myocarditis and Cardiomyopathy [see Warnings and Precautions (5.6) ].
• Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions (5.7) ].
• Eosinophilia [see Warnings and Precautions (5.8) ].
• QT Interval Prolongation [see Warnings and Precautions (5.9) ].
• Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.10) ].
• Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.11) ].
• Hepatotoxicity .
• Fever [see Warnings and Precautions (5.13) ].
• Pulmonary Embolism [see Warnings and Precautions (5.14) ].
• Anticholinergic Toxicity [see Warnings and Precautions (5.15) ].
• Interference with Cognitive and Motor Performance [see Warnings and Precautions (5.16) ].
• Tardive Dyskinesia [see Warnings and Precautions (5.17) ].
• Cerebrovascular Adverse Reactions [see Warnings and Precautions (5.18) ].
• Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation [see Warnings and Precautions (5.19) ].

Most common adverse reactions (≥5%) were: CNS reactions (sedation, dizziness/vertigo, headache, and tremor); cardiovascular reactions (tachycardia, hypotension, and syncope); autonomic nervous system reactions (hypersalivation, sweating, dry mouth, and visual disturbances); gastrointestinal reactions (constipation and nausea); and fever (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals, at 1-800-520-5568 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions (>5%) across Elcrit clinical trials were: CNS reactions, including sedation, dizziness/vertigo, headache, and tremor; cardiovascular reactions, including tachycardia, hypotension, and syncope; autonomic nervous system reactions, including hypersalivation, sweating, dry mouth, and visual disturbances; gastrointestinal reactions, including constipation and nausea; and fever. Table 9 summarizes the most commonly reported adverse reactions (>5%) in clozapine-treated patients (compared to chlorpromazine-treated patients) in the pivotal, 6-week, controlled trial in treatment-resistant schizophrenia.

Table 9: Common Adverse Reactions (≥5%) in the 6-Week, Randomized, Chlorpromazine-controlled Trial in Treatment-Resistant Schizophrenia

Table 10 summarizes the adverse reactions reported in clozapine-treated patients at a frequency of 2% or greater across all Elcrit studies (excluding the 2-year InterSePT Study). These rates are not adjusted for duration of exposure.

Table 10: Adverse Reactions (≥2%) Reported in Clozapine-treated Patients (N=842) across all Elcrit Studies (excluding the 2-year InterSePT Study)

Table 11 summarizes the most commonly reported adverse reactions (>10% of the Elcrit or olanzapine group) in the InterSePT Study. This was an adequate and well-controlled, two-year study evaluating the efficacy of Elcrit relative to olanzapine in reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. The rates are not adjusted for duration of exposure.

Table 11: Incidence of Adverse Reactions in Patients Treated with Elcrit or Olanzapine in the InterSePT Study (≥10% in the Elcrit or olanzapine group)

Dystonia

Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Elcrit. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Central Nervous System

Delirium, EEG abnormal, myoclonus, paresthesia, possible cataplexy, status epilepticus, obsessive compulsive symptoms, and post-discontinuation cholinergic rebound adverse reactions.

Cardiovascular System

Atrial or ventricular fibrillation, ventricular tachycardia, QT interval prolongation, Torsades de Pointes, myocardial infarction, cardiac arrest, and periorbital edema.

Endocrine System

Pseudopheochromocytoma.

Gastrointestinal System

Acute pancreatitis, dysphagia, salivary gland swelling.

Hepatobiliary System

Cholestasis, hepatitis, jaundice, hepatotoxicity, hepatic steatosis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, liver injury (hepatic, cholestatic, and mixed), and liver failure.

Immune System Disorders

Angioedema, leukocytoclastic vasculitis.

Urogenital System

Acute interstitial nephritis, nocturnal enuresis, priapism, and renal failure.

Skin and Subcutaneous Tissue Disorders

Hypersensitivity reactions: photosensitivity, vasculitis, erythema multiforme, skin pigmentation disorder, and Stevens-Johnson Syndrome.

Musculoskeletal System and Connective Tissue Disorders

Myasthenic syndrome, rhabdomyolysis, and systemic lupus erythematosus.

Respiratory System

Aspiration, pleural effusion, pneumonia, lower respiratory tract infection.

Hemic and Lymphatic System

Mild, moderate, or severe leukopenia, agranulocytosis, granulocytopenia, WBC decreased, deep vein thrombosis, elevated hemoglobin/hematocrit, erythrocyte sedimentation rate (ESR) increased, sepsis, thrombocytosis, and thrombocytopenia.

Vision Disorders

Narrow-angle glaucoma.

Miscellaneous

Creatine phosphokinase elevation, hyperuricemia, hyponatremia, and weight loss.

7 DRUG INTERACTIONS

• Concomitant use of Strong CYP1A2 Inhibitors: Reduce Elcrit dose to one third when coadministered with strong CYP1A2 inhibitors (2.7, 7.1).
• Concomitant use of Strong CYP3A4 Inducers is not recommended (2.7, 7.1).
• Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing Elcrit dose when CYP1A2 (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued (2.7, 7.1).

7.1 Potential for Other Drugs to Affect Elcrit

Elcrit is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering Elcrit concomitantly with drugs that are inducers or inhibitors of these enzymes.

CYP1A2 Inhibitors

Concomitant use of Elcrit and CYP1A2 inhibitors can increase plasma levels of Elcrit, potentially resulting in adverse reactions. Reduce the Elcrit dose to one third of the original dose when Elcrit is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The Elcrit dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued .

Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when Elcrit is coadministered with these inhibitors. Consider reducing the Elcrit dosage if necessary .

CYP2D6 and CYP3A4 Inhibitors

Concomitant treatment with Elcrit and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase Elcrit levels and lead to adverse reactions . Use caution and monitor patients closely when using such inhibitors. Consider reducing the Elcrit dose .

CYP1A2 and CYP3A4 Inducers

Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of Elcrit, resulting in decreased effectiveness of Elcrit. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John’s wort, and rifampin. It may be necessary to increase the Elcrit dose if used concomitantly with inducers of these enzymes. However, concomitant use of Elcrit and strong CYP3A4 inducers is not recommended .

Consider reducing the Elcrit dosage when discontinuing coadministered enzyme inducers, because discontinuation of inducers can result in increased Elcrit plasma levels and an increased risk of adverse reactions .

Drugs that Cause QT Interval Prolongation

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of Elcrit. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) [see Warnings and Precautions (5.9) ].

7.2 Potential for Elcrit to Affect Other Drugs

Concomitant use of Elcrit with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering Elcrit with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).

8 USE IN SPECIFIC POPULATIONS

• Nursing Mothers: Discontinue drug or discontinue nursing, taking into consideration importance of drug to mother.

8.1 Pregnancy

Pregnancy Category B

Risk Summary

There are no adequate or well-controlled studies of Elcrit in pregnant women.

Reproduction studies have been performed in rats and rabbits at doses up to 0.4 and 0.9 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m² body surface area basis. The studies revealed no evidence of impaired fertility or harm to the fetus due to Elcrit. Because animal reproduction studies are not always predictive of human response, Elcrit should be used during pregnancy only if clearly needed.

Clinical Considerations

Consider the risk of exacerbation of psychosis when discontinuing or changing treatment with antipsychotic medications during pregnancy and postpartum. Consider early screening for gestational diabetes for patients treated with antipsychotic medications [see Warnings and Precautions (5.10) ]. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Monitor neonates for symptoms of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding difficulties. The severity of complications can vary from self-limited symptoms to some neonates requiring intensive care unit support and prolonged hospitalization.

Animal Data

In embryofetal developmental studies, Elcrit had no effects on maternal parameters, litter sizes, or fetal parameters when administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 0.4 and 0.9 times, respectively, the MRHD of 900 mg/day on a mg/m² body surface area basis.

In peri/postnatal developmental studies, pregnant female rats were administered Elcrit over the last third of pregnancy and until day 21 postpartum. Observations were made on fetuses at birth and during the postnatal period; the offspring were allowed to reach sexual maturity and mated. Elcrit caused a decrease in maternal body weight but had no effects on litter size or body weights of either F1 or F2 generations at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m² body surface area basis.

8.3 Nursing Mothers

Elcrit is present in human milk. Because of the potential for serious adverse reactions in nursing infants from Elcrit, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

There have not been sufficient numbers of geriatric patients in clinical studies utilizing Elcrit to determine whether those over 65 years of age differ from younger subjects in their response to Elcrit.

Orthostatic hypotension and tachycardia can occur with Elcrit treatment . Elderly patients, particularly those with compromised cardiovascular functioning, may be more susceptible to these effects.

Elderly patients may be particularly susceptible to the anticholinergic effects of Elcrit, such as urinary retention and constipation [see Warnings and Precautions (5.15) ].

Carefully select Elcrit doses in elderly patients, taking into consideration their greater frequency of decreased hepatic, renal, or cardiac function, as well as other concomitant disease and other drug therapy. Clinical experience suggests that the prevalence of tardive dyskinesia appears to be highest among the elderly; especially elderly women [see Warnings and Precautions (5.17) ].

8.6 Patients with Renal or Hepatic Impairment

Dose reduction may be necessary in patients with significant impairment of renal or hepatic function. Elcrit concentrations may be increased in these patients, because Elcrit is almost completely metabolized and then excreted .

8.7 CYP2D6 Poor Metabolizers

Dose reduction may be necessary in patients who are CYP2D6 poor metabolizers. Elcrit concentrations may be increased in these patients, because Elcrit is almost completely metabolized and then excreted .

8.8 Hospice Patients

For hospice patients (i.e., terminally ill patients with an estimated life expectancy of 6 months or less), the prescriber may reduce the ANC monitoring frequency to once every 6 months, after a discussion with the patient and his/her caregiver. Individual treatment decisions should weigh the importance of monitoring ANC in the context of the need to control psychiatric symptoms and the patient's terminal illness.

10 OVERDOSAGE

10.1 Overdosage Experience

The most commonly reported signs and symptoms associated with Elcrit overdose are: sedation, delirium, coma, tachycardia, hypotension, respiratory depression or failure, and hypersalivation. There are reports of aspiration pneumonia, cardiac arrhythmias, and seizure. Fatal overdoses have been reported with Elcrit, generally at doses above 2500 mg. There have also been reports of patients recovering from overdoses well in excess of 4 g.

10.2 Management of Overdosage

For the most up-to-date information on the management of Elcrit overdosage, contact a certified Regional Poison Control Center (1-800-222-1222). Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians’ Desk Reference^® , a registered trademark of PDR Network. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general symptomatic and supportive measures. There are no specific antidotes for Elcrit.

In managing overdosage, consider the possibility of multiple-drug involvement.

11 DESCRIPTION

Elcrit, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.

The structural formula is:

Elcrit is available as a free-flowing yellow suspension. Each mL contains 50 mg of Elcrit.

The active component of Elcrit is Elcrit. The remaining components are glycerin, sorbitol (non-crystallizing), sodium dihydrogen phosphate dihydrate, xanthan gum, sodium methylparaben, sodium propylparaben, povidone, water, and sodium hydroxide to adjust to a pH range of 6.5 – 7.0.

Description: 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of Elcrit is unknown. However, it has been proposed that the therapeutic efficacy of Elcrit in schizophrenia is mediated through antagonism of the dopamine type 2 and the serotonin type 2A (5-HT_2A) receptors. Elcrit also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.

12.2 Pharmacodynamics

Elcrit demonstrated binding affinity to the following receptors: histamine H₁ (K_i 1.1 nM), adrenergic α_1A (K_i 1.6 nM), serotonin 5-HT₆ (K_i 4 nM), serotonin 5-HT_2A (K_i 5.4 nM), muscarinic M₁ (K_i 6.2 nM), serotonin 5-HT₇ (K_i 6.3 nM), serotonin 5-HT_2C (K_i 9.4 nM), dopamine D₄ (K_i 24 nM), adrenergic α_2A (K_i 90 nM), serotonin 5-HT₃ (K_i 95 nM), serotonin 5-HT_1A (K_i 120 nM), dopamine D₂ (K_i 160 nM), dopamine D₁ (K_i 270 nM), dopamine D₅ (K_i 454 nM), and dopamine D₃ (K_i 555 nM).

Elcrit causes little or no prolactin elevation.

Clinical electroencephalogram (EEG) studies demonstrated that Elcrit increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during Elcrit therapy. REM sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after falling asleep.

12.3 Pharmacokinetics

Absorption

In man, Elcrit tablets (25 mg and 100 mg) are equally bioavailable relative to a Elcrit solution. Elcrit Oral Suspension is bioequivalent to Elcrit marketed tablets.

Following oral administration of 100 mg to 800 mg Elcrit, once daily, the average steady-state peak plasma concentration was 275 ng/mL (range: 105 - 723 ng/mL), occurring at the average of 2.2 hours (range: 1 - 3.5 hours) after dosing. The average minimum concentration at steady-state was 75 ng/mL (range: 11 - 198 ng/mL).

When Elcrit was administered after a high fat meal there was no effect on the AUC_ss or C_{min, ss}, however C_max was reduced about 20%, and there was a slight delay in T_max of 0.5 hour from a median T_max of 2.0 hours under fasted conditions to 2.5 hours under fed conditions. The decrease in C_max is not considered clinically relevant. Therefore Elcrit may be taken without regard to meals.

Distribution

Elcrit is approximately 97% bound to serum proteins. The interaction between Elcrit and other highly protein-bound drugs has not been fully evaluated but may be important .

Metabolism and Excretion

Elcrit is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. Elcrit is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The demethylated, hydroxylated, and N-oxide derivatives are components in both urine and feces. Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and N-oxide derivatives were inactive. The mean elimination half-life of Elcrit after a single 75 mg dose was 8 hours (range: 4-12 hours), compared to a mean elimination half-life of 12 hours (range: 4-66 hours), after achieving steady-state with 100 mg twice daily dosing.

A comparison of single-dose and multiple-dose administration of Elcrit demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady-state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum Elcrit plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.

Drug-Drug Interaction Studies

Fluvoxamine

A pharmacokinetic study was conducted in 16 schizophrenic patients who received Elcrit under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of Elcrit and its metabolites, N-desmethylclozapine and Elcrit N-oxide, were elevated about three-fold compared to baseline steady-state concentrations.

Paroxetine, Fluoxetine, and Sertraline

In a study of schizophrenic patients (n=14) who received Elcrit under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of Elcrit and its metabolites. However, other published reports describe modest elevations (less than two-fold) of Elcrit and metabolite concentrations when Elcrit was taken with paroxetine, fluoxetine, and sertraline.

Specific Population Studies

Renal or Hepatic Impairment

No specific pharmacokinetic studies were conducted to investigate the effects of renal or hepatic impairment on the pharmacokinetics of Elcrit. Higher Elcrit plasma concentrations are likely in patients with significant renal or hepatic impairment when given usual doses.

CYP2D6 Poor Metabolizers

A subset (3%–10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of Elcrit when given usual doses.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

No carcinogenic potential was demonstrated in long-term studies in mice and rats at doses up to 0.3 times and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m² body surface area basis.

Mutagenesis

Elcrit was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the in vitro mammalian V79 in Chinese hamster cells, the in vitro unscheduled DNA synthesis in rat hepatocytes, or the in vivo micronucleus assay in mice.

Impairment of Fertility

Elcrit had no effect on any parameters of fertility, pregnancy, fetal weight, or postnatal development when administered orally to male rats 70 days before mating and to female rats for 14 days before mating at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m² body surface area basis.

14 CLINICAL STUDIES

14.1 Treatment-Resistant Schizophrenia

The efficacy of Elcrit in treatment-resistant schizophrenia was established in a multicenter, randomized, double-blind, active-controlled study in patients with a DSM-III diagnosis of schizophrenia who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions – Severity Scale score of at least 4 (moderately ill).

In the prospective, lead-in phase of the trial, all patients (N=305) initially received single-blind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6-week trial. Patients with an inadequate response to haloperidol (n=268) were randomized to double-blind treatment with Elcrit (N=126) or chlorpromazine (N=142). The maximum daily Elcrit dose was 900 mg; the mean daily dose was >600 mg). The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was >1200 mg.

The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of <3 (mildly ill), or (2) a BPRS score of <35, at the end of 6 weeks of treatment. Approximately 88% of patients from the Elcrit and chlorpromazine groups completed the 6-week trial. At the end of six weeks, 30% of the Elcrit group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant (p<0.001). The mean change in total BPRS score was -16 and -5 in the Elcrit and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the Elcrit and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the Elcrit and chlorpromazine group, respectively. These changes in the Elcrit group were statistically significantly greater than in the chlorpromazine group (p<0.001 in each analysis).

14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

The effectiveness of Elcrit in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePT, a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of Elcrit (Clozaril^®) versus olanzapine (Zyprexa^®, a registered trademark of Eli Lilly and Company) in 956 patients with schizophrenia or schizoaffective disorder (DSM-IV) who were judged to be at risk for recurrent suicidal behavior. Only about one-fourth of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met one of the following criteria:

• They had attempted suicide within the three years prior to their baseline evaluation.
• They had been hospitalized to prevent a suicide attempt within the three years prior to their baseline evaluation.
• They demonstrated moderate-to-severe suicidal ideation with a depressive component within one week prior to their baseline evaluation.
• They demonstrated moderate-to-severe suicidal ideation accompanied by command hallucinations to do self-harm within one week prior to their baseline evaluation.

Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200–900 mg/day for Elcrit and 5–20 mg/day for olanzapine. For the 956 patients who received Elcrit or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, and 28% with mood stabilizers. There was significantly greater use of concomitant psychotropic medications among the patients in the olanzapine group.

The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide; (2) hospitalization due to imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by “much worsening” or “very much worsening” from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the Suicide Monitoring Board (SMB), a group of experts blinded to patient data.

A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with schizophrenia, and the remainder (38%) were diagnosed with schizoaffective disorder. Only about one-fourth of the total patient population (27%) was identified as “treatment-resistant” at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range: 18–69). Most patients were Caucasian (71%), 15% were Black, 1% were Asian, and 13% were classified as being of “other” races.

Patients treated with Elcrit had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of Elcrit in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of Elcrit over olanzapine.

The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for Elcrit patients than for olanzapine patients at Week 104: Elcrit 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 1).

Figure 1. Cumulative Probability of a Significant Suicide Attempt or Hospitalization to Prevent Suicide in Patients with Schizophrenia or Schizoaffective Disorder at High Risk of Suicidality

Figure-02 Cumulative Probability

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Oral Suspension

Free-flowing, yellow suspension in amber bottle containing 100 mL. Each box contains 1 x 1 mL oral syringe, 1 x 9 mL oral syringe and 1 bottle adaptor.

NDC No. 18860-121-01

16.2 Storage and Handling

Store Elcrit at or below 25°C (77°F). Do not refrigerate or freeze. Protect from light. Shake well for 10 seconds before use.

The suspension is stable for 100 days after initial bottle opening.

Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION

Discuss the following issues with patients and caregivers:

• Severe Neutropenia
• Instruct patients (and caregivers) beginning treatment with Elcrit about the risk of developing severe neutropenia and infection.
• Instruct patients to immediately report to their physician any symptom or sign of infection (e.g., flu-like illness; fever; lethargy; general weakness or malaise; mucus membrane ulceration; skin, pharyngeal, vaginal, urinary, or pulmonary infection; or extreme weakness or lethargy) occurring at any time during Elcrit therapy, to aid in evaluation for neutropenia and to institute prompt and appropriate management [see Warnings and Precautions (5.1), (5.11) , and (5.13)].
• Inform patients and caregivers Elcrit is available only through a restricted program called the Elcrit REMS Program designed to ensure the required blood monitoring, in order to reduce the risk of developing severe neutropenia. Advise patients and caregivers of the importance of having blood tested as follows:
  • Weekly blood tests are required for the first 6 months.
  • An ANC is required every 2 weeks for the next 6 months if an acceptable ANC is maintained during the first 6 months of continuous therapy.
  • An ANC is required once every 4 weeks thereafter if an acceptable ANC is maintained during the second 6 months of continuous therapy.
• Elcrit is available only from certified pharmacies participating in the program. Provide patients (and caregivers) with website information and the telephone number on how to obtain the product.
• Orthostatic Hypotension, Bradycardia, and Syncope: Inform patients and caregivers about the risk of orthostatic hypotension and syncope, especially during the period of initial dose titration. Instruct them to strictly follow the clinician’s instructions for dosage and administration. Advise patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of bradycardia or arrhythmia .
• Falls: Inform patients of the risk of falls, which may lead to fractures or other injuries .
• Seizures: Inform patients and caregivers about the significant risk of seizure during Elcrit treatment. Caution them about driving and any other potentially hazardous activity while taking Elcrit [see Warnings and Precautions (5.5) ].
• QT Interval Prolongation: Advise patients to consult their clinician immediately if they feel faint, lose consciousness, or have signs or symptoms suggestive of arrhythmia. Instruct patients to not take Elcrit with other drugs that cause QT interval prolongation. Instruct patients to inform their clinicians that they are taking Elcrit before any new drug [see Warnings and Precautions (5.9) and Drug Interactions (7.1)].
• Metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain): Educate patients and caregivers about the risk of metabolic changes and the need for specific monitoring. The risks include hyperglycemia and diabetes mellitus, dyslipidemia, weight gain, and cardiovascular reactions. Educate patients and caregivers about the symptoms of hyperglycemia (high blood sugar) and diabetes mellitus (e.g., polydipsia, polyuria, polyphagia, and weakness). Monitor all patients for these symptoms. Patients who are diagnosed with diabetes or have risk factors for diabetes (obesity, family history of diabetes) should have their fasting blood glucose monitored before beginning treatment and periodically during treatment. Patients who develop symptoms of hyperglycemia should have assessments of fasting glucose. Clinical monitoring of weight is recommended [see Warnings and Precautions (5.10) ].
• Interference with Cognitive and Motor Performance: Because Elcrit may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Elcrit therapy does not affect them adversely [see Warnings and Precautions (5.16) ].
• Hepatotoxicity: Instruct patients to immediately report to their physician any symptoms or signs of potential liver injury (e.g. fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy) .
• Missed Doses and Re-Initiating Treatment: Inform patients and caregivers that if the patient misses taking Elcrit for more than 2 days, they should not restart his or her medication at the same dosage but should contact their physician for dosing instructions .
• Pregnancy: Patients and caregivers should notify the clinician if the patient becomes pregnant or intends to become pregnant during therapy .
• Nursing: Advise patients and caregivers that the patient should not breast feed an infant if she is taking Elcrit .
• Concomitant Medication: Advise patients to inform their health care provider if they are taking, or plan to take, any prescription or over-the-counter drugs; there is a potential for significant drug-drug interactions .
• Patient Instructions for Use: Educate the patient and caregiver about the Patient Instructions for Use if Elcrit will be administered at home. Discuss the specific steps for administering the prescribed dose using the oral syringe .

Distributed by:

Jazz Pharmaceuticals, Inc.

Palo Alto, CA 94304

U.S. Patent No. 8057811

Elcrit^® is a trademark of Jazz Pharmaceuticals plc or its subsidiaries.

Revised: February 2017

Patient Information

Elcrit^® (VER sa kloz)

(clozapine)

Oral Suspension

Read this Patient Information before you start taking Elcrit and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about Elcrit?

Elcrit can cause serious side effects, including:

1. Severe neutropenia, a blood disorder that can lead to serious infections and death. Severe neutropenia means that you do not have enough of certain white blood cells to fight infection. Tell your healthcare provider right away if you have any of the following symptoms or signs of neutropenia or infection:

• Skin, throat, urinary tract, vaginal, pneumonia, or any other infection
• Fever or chills
• Sores or ulcers inside your mouth, gums or on your skin
• Wounds that take a long time to heal
• Feel like you have the flu
• Pain or burning while urinating
• Unusual vaginal discharge or itching
• Abdominal pain
• Sores or pain in or around your rectal area
• Feel extremely tired or weak

If you have symptoms of severe neutropenia or infection you will need to have a blood test right away to check if Elcrit is causing your symptoms. You must have frequent blood tests while taking Elcrit so your healthcare provider can make sure you are not getting severe neutropenia or infection.

Elcrit is available only through a restricted program called the Elcrit REMS Program. This program makes sure that you will receive each refill of Elcrit only if you have a blood test and your blood test result is acceptable to your healthcare provider.

During your first 6 months of Elcrit treatment, you will have weekly blood tests. If you have not taken Elcrit before, you will need weekly blood tests when you first start Elcrit. If you have acceptable blood test results during your first 6 months of Elcrit treatment, you can have a blood test every other week for the next 6 months. After a year of acceptable blood test results, you can have blood tests every 4 weeks while you are taking Elcrit.

2. Decreased blood pressure (orthostatic hypotension), slow heart rate (bradycardia), or fainting (syncope) that can lead to death. Lightheadedness or fainting caused by a sudden change in your heart rate and blood pressure when you rise too quickly from a sitting or lying position can happen while you take Elcrit and can be life threatening. These problems may happen more often when you are first starting treatment with Elcrit or when your dose is increased. Tell your healthcare provider right away if you feel faint, lose consciousness, or have symptoms of slow heart rate or an irregular heart rhythm.

3. Seizures. Seizures can occur during Elcrit treatment. Be especially careful while driving or during any other dangerous activity while taking Elcrit.

4. Myocarditis (heart muscle inflammation) and cardiomyopathy (heart muscle weakness) that may lead to death. Symptoms of myocarditis and cardiomyopathy include:

5. Higher risk of death in elderly people with memory loss (dementia) or psychosis. Elcrit can increase the risk of death in elderly people who have dementia. Elcrit is not for treating psychosis in elderly people with dementia.

What is Elcrit?

Elcrit is a prescription antipsychotic medicine used to treat people with certain types of schizophrenia, including people who:

• are not helped by other schizophrenia medicines
• have been suicidal and may be at risk of suicidal behavior again

It is not known if Elcrit is safe and effective in children.

Who should not take Elcrit?

Do not take Elcrit if you:

• have blood problems called neutropenia
• are allergic to Elcrit or any of the ingredients in Elcrit. See the end of this Patient Information Leaflet for a complete list of ingredients in Elcrit.

What should I tell my healthcare provider before taking Elcrit?

Before you take Elcrit, tell your healthcare provider about all of your medical conditions, including if you:

• have or have had heart problems or a family history of heart problems including heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
• have or have had liver or kidney problems
• have or have had seizures or epilepsy
• have or have had low levels of potassium or magnesium in your blood
• have diabetes
• have increased pressure in your eyes (glaucoma)
• have had Neuroleptic Malignant Syndrome (NMS)
• have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
• have or have had diarrhea or constipation
• have or have had an enlarged prostate gland
• smoke tobacco
• plan to stop smoking tobacco while taking Elcrit
• use products containing caffeine
• are pregnant or plan to become pregnant. It is not known if Elcrit will harm your unborn baby. Call your healthcare provider right away if you become pregnant while taking Elcrit.
• are breastfeeding or plan to breastfeed. Elcrit can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take Elcrit. Do not breastfeed while taking Elcrit.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

Elcrit and other medicines may affect each other causing side effects.

Especially tell your healthcare provider if you take:

• chemotherapy, radiation, or other medicines that cause agranulocytosis, neutropenia, low white blood cell count, or affect your bone marrow
• other antipsychotics or other medicines that can affect the amount of Elcrit in your blood
• medicines used to treat anxiety, relax your muscles, or help you sleep
• any medicines that make you feel sleepy
• antibiotics
• medicines used to treat heart problems
• medicines used to lower the amount of water in your body (diuretics)
• medicines used for birth control

Ask your healthcare provider for a list of these medicines if you are not sure.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take Elcrit?

• Read the “Instructions for Use” at the end of this Patient Information for specific information about the right way to use Elcrit.
• Your pharmacist should go over the instructions for how to use Elcrit with you when you receive your first prescription.
• Take Elcrit exactly as your healthcare provider tells you to take it. Talk to your healthcare provider or pharmacist if you are not sure how to take Elcrit.
• Do not change your dose or stop taking Elcrit without talking to your healthcare provider.

The symptoms of Elcrit overdose can include:

If you miss a dose of Elcrit for more than 2 days, check with your healthcare provider before starting to take it again to make sure you take the correct dose.

What should I avoid while taking Elcrit?

• You should not drink alcohol while taking Elcrit. It can increase your chances of getting serious side effects.
• Do not drive, operate machinery, swim, climb, or do other dangerous activities until you know how Elcrit affects you.

What are the possible side effects of Elcrit?

Elcrit may cause serious side effects, including:

• See "What is the most important information I should know about Elcrit?"
• high count of a certain white blood cell (eosinophilia)
• problems with your heartbeat. These heart problems can cause death. Call your healthcare provider right away if you have any of these symptoms:
  • passing out or feeling like you will pass out
  • dizziness
  • feeling as if your heart is pounding or missing beats
• high blood sugar (diabetes) and changes in the fat levels in your blood (dyslipidemia)
• Neuroleptic Malignant Syndrome (NMS). NMS is a rare but very serious problem that can happen in people who take Elcrit. NMS can cause death and must be treated in a hospital. Call your healthcare provider right away if you become severely ill and have any of these symptoms:
  • high fever
  • excessive sweating
  • stiff muscles
  • confusion
  • changes in your breathing, heartbeat and blood pressure
• falls, which may lead to fractures or other injuries
• liver problems. Call your healthcare provider right away if you have any of these symptoms:
  • nausea
  • vomiting
  • loss of appetite
  • feel tired
  • pain on the right side of your stomach (abdomen)
  • yellowing of your skin or the whites of your eyes
• fever. Some people may have a fever that comes and goes while they take Elcrit. This happens more often in the first 3 weeks you take Elcrit. Talk to your healthcare provider if you have a fever.
• blood clot in your lung (pulmonary embolism) or in the veins of your legs (deep-vein thrombosis). Get emergency help right away if you have symptoms of a blood clot including:
  • chest pain and shortness of breath
  • swelling or pain in your leg, ankle or foot
  • warm feeling in the skin of your affected leg
  • changes in your skin color such as turning pale or blue
• a problem that includes dry mouth, increased sweating, increased pulse rate and constipation (anticholinergic toxicity)
• problems thinking clearly and moving your body
• uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
• stroke in elderly people (cerebrovascular problems)

The most common side effects of Elcrit include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Elcrit. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Elcrit?

• Store Elcrit at room temperature between 68°F to 77°F (20°C to 25°C).
• Do not refrigerate or freeze Elcrit.
• Protect Elcrit from light.
• Shake your Elcrit bottle well for 10 seconds before each use.

Keep Elcrit and all medicines out of the reach of children.

General information about the safe and effective use of Elcrit

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use Elcrit for a condition for which it was not prescribed. Do not give Elcrit to other people, even if they have the same symptoms that you have. It may harm them.

This Patient Information Leaflet summarizes the most important information about Elcrit. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for more information about Elcrit that is written for healthcare professionals.

For more information, go to www. VERSACLOZ.com or call 1-800-520-5568.

What are the ingredients in Elcrit?

Active ingredient: Elcrit

Inactive ingredients: glycerin, sorbitol (non-crystallizing), sodium dihydrogen phosphate dihydrate, xanthan gum, sodium methylparaben, sodium propylparaben, povidone, water, and sodium hydroxide

Instructions for Use

Elcrit^® (VER sa kloz)

(clozapine)

Oral Suspension

Supplies you will need to take your Elcrit dose:

• Elcrit^® Oral Suspension bottle
• a bottle neck adaptor
• the correct oral syringe to measure your dose
  • If your dose is 1 mL (50 mg) or less, use the smaller 1 mL oral syringe.
  • If your dose is more than 1 mL (50 mg), use the larger 9 mL oral syringe.

Disposal of your oral syringe, empty Elcrit bottle and bottle neck adaptor:

Place the cap back on the empty Elcrit bottle before you throw it away. The oral syringe, empty bottle and bottle neck adaptor should be placed in your household trash when you finish your bottle of Elcrit. The oral syringe should not be shared with other people or used for medicines other than Elcrit.

Distributed by:

Jazz Pharmaceuticals, Inc.

Palo Alto, CA 94304 USA

This Patient Information and the Instructions for Use have been approved by the U.S. Food and Drug Administration.

Revised: February 2017

symptoms of myocarditis and cardiomyopathy symptoms side effects Figure-03 Patient Use Figure A Step 1 Figure B Step 2 Figure C Step 3 Figure D-01 Figure D-02 Step 4 Figure E Step 5 Figure F Step 6 Figure G Step 7 Figure H Step 8 Figure I Step 9 Figure J Step 10 Figure K Step 11 Figure L Step 12 Figure M Step 13 Figure N Step 14

Rx Only

Elcrit^®

(clozapine) Oral Suspension

50 mg/mL

Elcrit pharmaceutical active ingredients containing related brand and generic drugs:

• Clozapine

Elcrit available forms, composition, doses:

• N/A

Elcrit destination | category:

• Human:
• Atypical antipsychotics

Elcrit Anatomical Therapeutic Chemical codes:

• N05AH02 - Clozapine

Elcrit pharmaceutical companies:

• Pfizer

References

1. Dailymed."VERSACLOZ (CLOZAPINE) SUSPENSION [JAZZ PHARMACEUTICALS, INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
2. Dailymed."CLOZAPINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
3. "clozapine". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Depending on the reaction of the Elcrit after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Elcrit not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

Visitor reports

Visitor reviews

The information was verified by Dr. Rachana Salvi, MD Pharmacology